EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective randomized controlled phase 2 trials (Prodige35, Prodige37 and AFUGEM)

Shulin Zhao, Remy Nicolle, Julien Taieb, Laetitia Dahan, Raef Abdallah, Olivier Bouché, Jérôme Desrame, Jean-Marc Phelip, Ludovic Evesque, Faïza Khemissa Akouz, Louis de Mestier, Isabelle Trouilloud und 5 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218745 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Letters, 2026. Verfasst von Shulin Zhao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche des Cordeliers, INSERM UMRS1138, CNRS, Sorbonne Université, USPC, Université de Paris, Equipe Labellisée Ligue Nationale Contre l…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Pancreatic Neoplasms, Transcriptome. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Commission of the People's Republic of China, Shanghai Association for Science and Technology, Ministry of Higher Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the clinical applicability of previously established transcriptomic signatures (molecular subtypes, components and GemPred status) in metastatic pancreatic cancer, we conducted a retrospective pooled analysis of 178 patients from three phase 2 trials (PRODIGE35/37, AFUGEM; 2013-2016) testing first-line regimens (FOLFIRINOX, GemNab, FuNab, FOLFIRI3). RNA sequencing was performed on primary/metastatic tumors across French centers, with blinded assessment of subtypes (immune classical, pure basal-like, stroma-activated), quantitative components, and GemPred status. Primary endpoint: progression-free survival (PFS). Immune classical subtype showed superior median PFS (9.03 months) and OS (11.27 months) versus basal-like and stroma-activated subtypes (PFS: p = 0.015; OS: p = 0.010). Higher classical component correlated with improved OS (HR = 0.737, p = 0.005) but not PFS (HR = 0.90, p = 0.339). Inactive stroma predicted better PFS (HR = 0.66, p = 0.003) and OS (HR = 0.697, p = 0.013). GemPred-negative patients treated with FOLFIRINOX versus GemNab had higher ORR (46.9% vs. 19.1%, p = 0.046), longer PFS (8.2 vs. 2.3 months; HR = 2.28, p = 0.008), and OS (11.6 vs. 5.0 months; HR = 2.04, p = 0.021). No differences occurred in GemPred-positive patients. In a formal treatment-by-GemPred interaction analysis (FOLFIRINOX vs. GemNab), the interaction was significant for OS (adjusted p-interaction = 0.050) but not for PFS (adjusted p-interaction = 0.51). Transcriptomic signatures retain prognostic and predictive utility in metastatic pancreatic cancer, with GemPred representing a hypothesis-generating predictive signal for OS (e.g., a FOLFIRINOX OS benefit in GemPred-negative). Prospective validation is warranted for clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorPancreatic NeoplasmsTranscriptomeAdultAgedFemaleHumansMaleMiddle AgedFluorouracilFranceGene Expression ProfilingIrinotecanLeucovorinOxaliplatinPredictive Value of TestsPrognosisProgression-Free SurvivalProspective StudiesRetrospective StudiesClinical Trials, Phase II as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

ComponentsMetastaticMolecular subtypePancreatic adenocarcinomaPredictive valuePrognostic value

Substanzen

Biomarkers, TumorFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatin

Autor:innen und Institutionen

  • Centre de Recherche des Cordeliers, INSERM UMRS1138, CNRS, Sorbonne Université, USPC, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC 5096, Paris, France; Department of General Surgery,…
  • Université Paris Cité, INSERM, U1149, Centre de Recherche sur L'Inflammation (CRI), Paris, France.
  • Centre de Recherche des Cordeliers, INSERM UMRS1138, CNRS, Sorbonne Université, USPC, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC 5096, Paris, France; Paris Cité Université, Assista…
  • Hepato-Gastroenterology and Oncology Department, University Hospital La Timone, Marseille, France.
  • Centre de Recherche des Cordeliers, INSERM UMRS1138, CNRS, Sorbonne Université, USPC, Université de Paris, Equipe Labellisée Ligue Nationale Contre le Cancer, CNRS SNC 5096, Paris, France; Asssistance Publique - Hôpitau…
  • Department of Digestive Oncology, CHU Reims, URCA, Reims, France.

Förderung

  • National Health Commission of the People's Republic of China
  • Shanghai Association for Science and Technology
  • Ministry of Higher Education and Research
  • National League Against Cancer
  • National Centre for Scientific Research

Zitieren

APA

Zhao, S., Nicolle, R., Taieb, J., Dahan, L., Abdallah, R., Bouché, O., Desrame, J., Phelip, J. M., Evesque, L., Akouz, F. K., de Mestier, L., Trouilloud, I., Malka, D., Shen, B., Cros, J., Laurent-Puig, P., & Bachet, J. B. (2026). Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective randomized controlled phase 2 trials (Prodige35, Prodige37 and AFUGEM). Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218745

Vancouver

Zhao S, Nicolle R, Taieb J, Dahan L, Abdallah R, Bouché O, et al. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective randomized controlled phase 2 trials (Prodige35, Prodige37 and AFUGEM). Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218745

BibTeX
@article{Zhao2026,
  author = {Zhao, Shulin and Nicolle, Remy and Taieb, Julien and Dahan, Laetitia and Abdallah, Raef and Bouché, Olivier and Desrame, Jérôme and Phelip, Jean-Marc and Evesque, Ludovic and Akouz, Faïza Khemissa and de Mestier, Louis and Trouilloud, Isabelle and Malka, David and Shen, Baiyong and Cros, Jerome and Laurent-Puig, Pierre and Bachet, Jean-Baptiste},
  title = {Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective randomized controlled phase 2 trials (Prodige35, Prodige37 and AFUGEM)},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218745}
}
Kostenlos starten →